WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 315285
CAS#: 65928-58-7
Description: Dienogest is an orally active synthetic progesterone (or progestin). It is available for use as an oral contraceptive in combination with ethinylestradiol. It has antiandrogenic activity and as a result can improve androgenic symptoms. It is a non-ethinylated progestin which is structurally related to testosterone. Dienogest given in isolation is available for the treatment of endometriosis under the trade name Visanne. (Source: http://en.wikipedia.org/wiki/Dienogest).
MedKoo Cat#: 315285
Name: Dienogest
CAS#: 65928-58-7
Chemical Formula: C20H25NO2
Exact Mass: 311.18853
Molecular Weight: 311.418
Elemental Analysis: C, 77.14; H, 8.09; N, 4.50; O, 10.28
Synonym: BAY86-5258; BAY 86-5258; BAY-86-5258; Dinagest; Endometrion; M 18575; MJR-35; STS 557; Visanne; ZK 37659. Dienogest
IUPAC/Chemical Name: 2-((8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)acetonitrile
InChi Key: AZFLJNIPTRTECV-FUMNGEBKSA-N
InChi Code: InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1
SMILES Code: N#CC[C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(CCC4=C3CC[C@]12C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 311.418 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Taskin MI, Bilen C, Ergun A, Gencer N, Inceboz U. In vitro effects of estrogen and progesterone containing drugs on human erythrocyte carbonic anhydrase I and II isozymes in women smokers and nonsmokers. J Chin Med Assoc. 2015 Jul 31. pii: S1726-4901(15)00151-3. doi: 10.1016/j.jcma.2015.03.014. [Epub ahead of print] PubMed PMID: 26239150.
2: Rouskova D, Mittmann K, Schumacher U, Dietrich H, Zimmermann T. Effectiveness, tolerability and acceptance of a low-dosed estradiol/dienogest formulation (Lafamme 1 mg/2 mg) for the treatment of menopausal complaints: a non-interventional observational study over 6 cycles of 28 days. Gynecol Endocrinol. 2015 Aug 10:1-5. [Epub ahead of print] PubMed PMID: 26217921.
3: Ferrero S, Remorgida V, Venturini PL, Bizzarri N. Endometriosis: the effects of dienogest. BMJ Clin Evid. 2015 Jun 9;2015. pii: 0802. PubMed PMID: 26057101.
4: Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest enhances autophagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil Steril. 2015 Jun 11. pii: S0015-0282(15)00367-2. doi: 10.1016/j.fertnstert.2015.05.020. [Epub ahead of print] PubMed PMID: 26051103.
5: Lete I, Chabbert-Buffet N, Jamin C, Lello S, Lobo P, Nappi RE, Pintiaux A. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review. Eur J Contracept Reprod Health Care. 2015 May 28:1-15. [Epub ahead of print] PubMed PMID: 26007631.
6: Fawzy M, Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet. 2015 May 20. [Epub ahead of print] PubMed PMID: 25990480.
7: Strowitzki T, Faustmann T, Gerlinger C, Schumacher U, Ahlers C, Seitz C. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Womens Health. 2015 Apr 15;7:393-401. doi: 10.2147/IJWH.S77202. eCollection 2015. PubMed PMID: 25926759; PubMed Central PMCID: PMC4403681.
8: Takenaka M, Yano R, Hiraku Y, Shibata M, Hatano K, Yamamoto S, Sato K, Yamamoto K, Morishige K. Exploratory study of pre-surgical medications with dienogest or leuprorelin in laparoscopic cystectomy of endometrial cysts. J Obstet Gynaecol Res. 2015 Aug;41(8):1234-9. doi: 10.1111/jog.12701. Epub 2015 Apr 1. PubMed PMID: 25833348.
9: Angioni S, Nappi L, Pontis A, Sedda F, Luisi S, Mais V, Melis GB. Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study. Gynecol Endocrinol. 2015 May;31(5):406-8. doi: 10.3109/09513590.2015.1006617. Epub 2015 Mar 17. PubMed PMID: 25776993.
10: Mori T, Ito F, Matsushima H, Takaoka O, Koshiba A, Tanaka Y, Kusuki I, Kitawaki J. Dienogest reduces HSD17β1 expression and activity in endometriosis. J Endocrinol. 2015 May;225(2):69-76. doi: 10.1530/JOE-15-0052. Epub 2015 Mar 12. PubMed PMID: 25767055.
